Revolution Medicines - RVMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.25
  • Forecasted Upside: 49.77 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$19.53
▼ -0.19 (-0.96%)

This chart shows the closing price for RVMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revolution Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVMD

Analyst Price Target is $29.25
▲ +49.77% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $29.25, with a high forecast of $37.00 and a low forecast of $24.00. The average price target represents a 49.77% upside from the last price of $19.53.

This chart shows the closing price for RVMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Revolution Medicines. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2022HC WainwrightLower TargetBuy$40.00 ➝ $37.00Low
8/10/2022SVB LeerinkLower TargetOutperform$31.00 ➝ $30.00Low
5/20/2022Bank of AmericaInitiated CoverageNeutral$24.00High
5/9/2022SVB LeerinkReiterated RatingOutperformHigh
3/1/2022HC WainwrightBoost Target$38.00 ➝ $40.00High
3/1/2022Stifel NicolausUpgradeHold ➝ Buy$36.00 ➝ $26.00Medium
11/12/2021HC WainwrightBoost TargetBuy$31.00 ➝ $38.00High
9/22/2021Stifel NicolausInitiated CoverageHold$34.00Low
8/17/2021HC WainwrightLower TargetBuy$55.00 ➝ $31.00Medium
8/12/2021GuggenheimLower TargetBuy$52.00 ➝ $34.00High
8/12/2021SVB LeerinkLower TargetOutperform$46.00 ➝ $38.00High
8/12/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$49.00 ➝ $27.00High
6/29/2021HC WainwrightReiterated RatingBuy$55.00Low
6/20/2021SVB LeerinkReiterated RatingBuyMedium
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$49.00Medium
5/11/2021SVB LeerinkLower TargetOutperform$55.00 ➝ $46.00High
3/3/2021SVB LeerinkBoost TargetOutperform$46.00 ➝ $55.00High
1/29/2021JPMorgan Chase & Co.Boost Target$33.00 ➝ $44.00Low
10/26/2020HC WainwrightBoost TargetBuy$52.00 ➝ $54.00High
8/11/2020HC WainwrightLower TargetBuy$55.00 ➝ $52.00Low
8/10/2020SVB LeerinkLower TargetOutperform$40.00 ➝ $39.00Medium
6/23/2020HC WainwrightReiterated RatingBuy$55.00Medium
6/9/2020HC WainwrightReiterated RatingBuy$55.00Medium
5/27/2020HC WainwrightReiterated RatingBuy$55.00High
5/21/2020HC WainwrightInitiated CoverageBuy$55.00Medium
3/9/2020SVB LeerinkReiterated RatingOutperformHigh
3/9/2020JPMorgan Chase & Co.Initiated CoverageNeutral$32.00Low
3/9/2020CowenInitiated CoverageOutperformLow
3/9/2020GuggenheimInitiated CoverageBuy$50.00Low
(Data available from 10/4/2017 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/8/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/7/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/6/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/5/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/4/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/4/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

Revolution Medicines logo
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $19.53
Low: $19.35
High: $20.45

50 Day Range

MA: $21.59
Low: $17.46
High: $26.00

52 Week Range

Now: $19.53
Low: $14.08
High: $34.16

Volume

506,501 shs

Average Volume

915,355 shs

Market Capitalization

$1.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Revolution Medicines?

The following Wall Street research analysts have issued stock ratings on Revolution Medicines in the last twelve months: Bank of America Co., HC Wainwright, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for RVMD.

What is the current price target for Revolution Medicines?

4 Wall Street analysts have set twelve-month price targets for Revolution Medicines in the last year. Their average twelve-month price target is $29.25, suggesting a possible upside of 49.8%. HC Wainwright has the highest price target set, predicting RVMD will reach $37.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $24.00 for Revolution Medicines in the next year.
View the latest price targets for RVMD.

What is the current consensus analyst rating for Revolution Medicines?

Revolution Medicines currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVMD will outperform the market and that investors should add to their positions of Revolution Medicines.
View the latest ratings for RVMD.

What other companies compete with Revolution Medicines?

How do I contact Revolution Medicines' investor relations team?

Revolution Medicines' physical mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The company's listed phone number is 650-481-6801 and its investor relations email address is [email protected] The official website for Revolution Medicines is www.revmed.com. Learn More about contacing Revolution Medicines investor relations.